FMP
May 28, 2024 3:48 PM - Davit Kirakosyan
Chardan Capital Markets analysts initiated coverage on iBio (NYSE:IBIO) with a Buy rating and a price target of $5, noting they see significant potential in iBio's proprietary AI-guided drug discovery platform, which aims to create next-generation engineered antibodies for challenging targets while reducing development risks.
This marks a strategic shift for iBio, which acquired RubrYc Therapeutics in September 2022 for its AI-driven drug discovery capabilities and decided to divest its CDMO facility in November 2022, resulting in a workforce reduction of about 60%. iBio's recent partnership with AstralBio focuses on developing novel antibodies to treat obesity and other cardiometabolic conditions.
The analysts believe iBio has evolved into an intriguing micro-cap investment opportunity, suitable for investors with a longer-term perspective who are willing to balance the company's need to raise additional capital (expected in the first half of 2025) before any human clinical data is available. The core technology behind iBio's platform combines precision medicine biology with machine learning and AI.
Jan 16, 2024 4:18 PM - Samuel Abdelshahid
In the hustle and bustle of the trading world, having a trustworthy laptop is like having a reliable partner by your side. Making well-informed decisions and staying ahead of market trends become second nature with the right device. However, the quest for a budget-friendly trading laptop t...
Jan 21, 2024 4:00 AM - Parth Sanghvi
Introduction: In the world of financial analysis, a profound grasp of essential profitability metrics is vital. This blog delves into three pivotal metrics—ROE (Return on Equity), ROA (Return on Assets), and Net Profit Margin—offering clear insights without unnecessary complexity. Exploring RO...
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...